advisorsecurities master

RIGLRigel Pharmaceuticals Inc. (New)

CSNasdaq (XNAS)·USD

Identity

Security key
20971
Ticker
RIGL
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2000-11-29
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
RIGL

Detail

Enriched 2026-08-14 20:47

Market cap
$782,125,905.68
Shares outstanding (class)
18,502,080
Shares outstanding (weighted)
18,679,864
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
174
Location
SOUTH SAN FRANCISCO, CA
Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data